|
Sign In to gain access to subscriptions and/or personal tools.
|
The SCOPE Trial
Peter Sever
Imperial College of Science, Technology and Medicine, NHLI Division, Department of Clinical Pharmacology, QEQM Wing, St Mary's Hospital, London, W2 1NY, UK, p.sever{at}ic.ac.uk
The Study on Cognition and Prognosis in the Elderly (SCOPE) was designed to provide outcome data on cardiovascular endpoints and cognitive function in 4500 elderly hypertensive patients randomised to the angiotensin receptor blocker, candesartan, or to placebo and followed up for 4.5 years.
The primary endpoint of combined cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke was not significantly reduced by active treatment (relative risk reduction 11%, p=0.19). There was also no significant difference in the decline of cognitive function between the two treatment arms.
Active treatment of the placebo group (mainly hydrochlorothiazide) reduced the blood pressure differences between the treatment arms to only 3.2/1.6 mmHg, thus markedly reducing the overall power of the study. In a number of non-prespecified subgroup analyses, advantages of candesartan over placebo were reported.
Key Words: hypertension • outcome trial • cognitive function
References
- Hansson L., Lithell H., Skoog I. et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8:177-83.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Medical Research Council Working Party. MRC trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.[Abstract/Free Full Text]
- SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991;265:3255-64.[Abstract/Free Full Text]
- Staessen JA, Fagard R., Thijs L. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 1999 World Health Organisation - International Society of Hypertension Guidelines for the Managements of Hypertension. Guidelines Sub-committee. J Hypertens 1999; 17:151-83.[Web of Science][Medline]
[Order article via Infotrieve]
- Dahlöf B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mann J., Julius S. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-83.
- Davis BR, Cutler JA, Gordon DJ et al. for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-60.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sever PS, Dahlöf B., Poulter NR et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001;19: 1139-47.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 2,
61-62 (2002)
DOI: 10.3317/jraas.2002.018
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
